Latest Amides Stories
Sales of Breast Cancer Therapies are Expected to Almost Double Through 2023, Fueled by Growth in Several Distinct Market Segments, According to Findings from Decision Resources Group BURLINGTON,
As Pradaxa Lawsuit Claims Continue Boehringer Ingelheim Conducts Clinical Trials On Idarucizumab, A Potential Reversal Agent To Pradaxa Columbus, OH (PRWEB)
Wright & Schulte LLC Continues To Investigate Complaints That Janssen Pharmaceuticals Did Not Disclose The Lack of An Effective Means To Treat Uncontrolled Bleeding In Patients Taking Xarelto
RIDGEFIELD, Conn., Sept. 26, 2014 /PRNewswire/ - Boehringer Ingelheim applauds the U.S.
WHIPPANY, N.J., Sept. 24, 2014 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc.
- Boehringer Ingelheim obtains exclusive global rights for development and commercialization of CureVac's investigational therapeutic cancer vaccine CV9202 INGELHEIM and TUBINGEN, Germany,
Dr. Milton Packer and Dr. McMurray will be presenting these results for the first time in the United States at the HFSA Annual Meeting LAS VEGAS, Sept.
--Phase 2a Trial is First to Use Crowdsourcing for Protocol Design and Telemonitoring for Patient Data Collection-- NEW YORK, Sept.
DALLAS, September 7, 2014 /PRNewswire/ -- MarketOptimizer.org adds "Acute Coronary Syndrome - US Drug Forecast and Market Analysis to 2023", a new research report to its
Eleven-month Increase in Median OS Reported with VT-122 plus Sorafenib, Compared to Sorafenib Alone.
- A woman chauffeur.
- A woman who operates an automobile.